M
Michael Recht
Researcher at Oregon Health & Science University
Publications - 130
Citations - 5200
Michael Recht is an academic researcher from Oregon Health & Science University. The author has contributed to research in topics: Medicine & Haemophilia. The author has an hindex of 28, co-authored 100 publications receiving 4248 citations. Previous affiliations of Michael Recht include Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.
Marilyn J. Manco-Johnson,Marilyn J. Manco-Johnson,Thomas C. Abshire,Amy D. Shapiro,Brenda Riske,Michele R. Hacker,Ray F. Kilcoyne,J. David Ingram,M L Manco-Johnson,Sharon Funk,Linda J. Jacobson,Leonard A. Valentino,W. Keith Hoots,George R. Buchanan,Donna DiMichele,Michael Recht,Deborah L Brown,Cindy A. Leissinger,Shirley Bleak,Alan R. Cohen,Prasad Mathew,Alison Matsunaga,Desiree Medeiros,Diane J. Nugent,Gregory Thomas,Alexis A. Thompson,Kevin McRedmond,J. Michael Soucie,Harlan Austin,Bruce L. Evatt +29 more
TL;DR: Prophylaxis with recombinant factor VIII can prevent joint damage and decrease the frequency of joint and other hemorrhages in young boys with severe hemophilia A.
Journal ArticleDOI
Long-term safety and efficacy of factor IX gene therapy in hemophilia B
Amit C. Nathwani,Ulreke M Reiss,Edward G. D. Tuddenham,Cecilia Rosales,Cecilia Rosales,Pratima Chowdary,Jenny McIntosh,Marco Della Peruta,Elsa Lheriteau,Nishal Patel,Deepak Raj,Deepak Raj,Anne Riddell,Jun Pie,Savita Rangarajan,Savita Rangarajan,David H. Bevan,Michael Recht,Yu-min P Shen,Kathleen Halka,Etiena Basner-Tschakarjan,Federico Mingozzi,Katherine A. High,James A. Allay,Mark A. Kay,Catherine Y.C. Ng,Junfang Zhou,Maria I Cancio,Christopher L. Morton,John T. Gray,Deo Kumar Srivastava,Arthur W. Nienhuis,Andrew M. Davidoff +32 more
TL;DR: In 10 patients with severe hemophilia B, the infusion of a single dose of AAV8 vector resulted in long-term therapeutic factor IX expression associated with clinical improvement, and with a follow-up period of up to 3 years, no late toxic effects from the therapy were reported.
Journal ArticleDOI
Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia.
Chengwen Li,Nattee Narkbunnam,Nattee Narkbunnam,Richard Jude Samulski,Aravind Asokan,Genlin Hu,L. J. Jacobson,M. J. Manco-Johnson,Paul E. Monahan,Marilyn J. Manco-Johnson,Brenda Riske,Ray F. Kilcoyne,M L Manco-Johnson,Sharon Funk,Linda J. Jacobson,J. David Ingram,Thomas C. Abshire,Thomas C. Abshire,Amy D. Shapiro,Michele R. Hacker,Leonard A. Valentino,W. Keith Hoots,Deborah L Brown,George R. Buchanan,Donna DiMichele,Michael Recht,Cindy A. Leissinger,Shirley Bleak,Alan R. Cohen,Prasad Mathew,Alison Matsunaga,Desiree Medeiros,Diane J. Nugent,Gregory Thomas,Alexis A. Thompson,Kevin McRedmond,J. Michael Soucie,Harlan Austin,Bruce L. Evatt +38 more
TL;DR: The results may guide rational design of clinical trials using alternative AAV serotypes and suggest that younger patients who are given AAV gene therapy will benefit from the lower prevalence of NAbs.
Journal ArticleDOI
Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia
TL;DR: A history of HCV and HIV infections, decreased joint range‐of‐motion, decreased activity levels, history of an inhibitor and low body weight predict bone loss and suggest a population to target for screening.
Journal ArticleDOI
Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.
Yvonne E. Chiu,Beth A. Drolet,Francine Blei,Manuel Carcao,Jason Fangusaro,Michael E. Kelly,Alfons Krol,Sabra Lofgren,Anthony J. Mancini,Denise W. Metry,Michael Recht,Robert A. Silverman,Wynnis L. Tom,Elena Pope +13 more
TL;DR: The varied responses to treatment, with only 36% responding in this series, demonstrate the need for further study of this medication before routine use for these indications.